Skip to main content

Market Overview

Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings

Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings
  • Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year.
  • Sales of $6.42 billion missed the consensus of $6.74 billion but grew 16% Y/Y.
  • Revenue from COVID-19 treatment, Veklury, was $1.5 billion and excluding Veklury, total sales decreased 11% Y/Y to $4.9 billion.
  • Sales of HIV treatments declined 12% to $3.7 billion as Hepatitis C drug revenue fell 30% to $510 million.
  • Cancer drugs Yescarta and Tecartus generated higher sales of $160 million and $31 million, respectively. Trodelvy, which Gilead recently acquired, brought in $72 million.
  • Guidance: For FY20, the company expects adjusted income of $6.75-$7.45, in line with the analyst consensus of $7.17. It guided for revenue of $23.7 billion to $25.1 billion in full-year product sales, versus analyst consensus of $24.78 billion.
  • Price Action: GILD shares are down 2.3% at $62.37 in the premarket session on the last check Friday.

Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Guidance Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at